

Supporting Information

Multi-Responsive Supramolecular Heparin-Based Biohybrid Metallogel Constructed by Controlled
Self-Assembly Based on Metal–Ligand, Host-Guest and Electrostatic Interactions

Gui-Yuan Wu,*^a Chao Liang,^a Hao Li,^a Xianyi Zhang,^a Guanxin Yao,^a Fan-Fan Zhu,^c Yi-Xiong Hu,^c

5 Guang-Qiang Yin,^c Wei Zheng,^{*b} Zhou Lu*^a

^a Anhui Province Key Laboratory of Optoelectronic Material Science and Technology, School of Physics and
Electronic Information, Anhui Normal University, Wuhu, 241002, China.

^b Department of Molecular and Macromolecular Chemistry, Graduate School of Engineering, Nagoya University,
Nagoya 464-8603, Japan.

10 ^c Shanghai Key Laboratory of Green Chemistry and Chemical Processes, School of Chemistry and Molecular
Engineering, East China Normal University, 3663 N. Zhongshan Road, Shanghai, China.

Table of Contents


1. Materials and methods.....	S2
2. Synthetic experimental details and characterizations of new compounds	S3
15 3. The construction and characterization of hybrid polypesudorotaxane.....	S9
4. Multiple nuclear NMR (¹ H and ¹³ C NMR) spectra and MS of new compounds.....	S14

1. Materials and methods

All solvents were dried according to standard procedures and all of them were degassed under N₂ for 30 minutes before use. All air-sensitive reactions were carried out under inert N₂ atmosphere. ¹H, ¹³C NMR and ³¹P NMR spectra were recorded on Bruker 400MHz Spectrometer (¹H: 400 MHz; ³¹P: 161.9 MHz) and 500MHz Spectrometer (¹H: 500MHz) at 298 K. The ¹H and ¹³C NMR chemical shifts are reported relative to the residual solvent signals, and ³¹P NMR resonances are referenced to an internal standard sample of 85% H₃PO₄ (δ 0.0). The SEM samples were prepared on clean Si substrates. To minimize sample charging, a thin layer of Au was deposited onto the samples before SEM examination. All the SEM images were obtained using a S-4800 (Hitachi Ltd.) with an accelerating voltage of 3.0-10.0 kV.

Synthetic experimental details and characterizations of new compounds

Scheme S1. The synthetic procedure for the donor **D**.



Synthesis of the donor D. A 100 mL Schlenk flask was charged with **S1** (370 mg, 1.07mmol),¹ 5 Cs_2CO_3 (929.09 mg, 4.81 mmol), **S2** (475.5 mg, 1.61 mmol), degassed, and back-filled three times with N_2 . Anhydrous CH_3COCH_3 (40mL) were introduced into the reaction flask by syringe. The reaction was stirred under an inert atmosphere at 60°C for a night. The solvent was extracted in $\text{CH}_2\text{Cl}_2/\text{H}_2\text{O}$ mixture (100/50 mL). The organic phase was washed with H_2O (3×100 mL). The organic phases were collected and dried over anhydrous Na_2SO_4 , and the solution was evaporated in vacuo.


10 After column chromatography on SiO_2 ($\text{CH}_2\text{Cl}_2\text{-CH}_3\text{OH}$ 0% to 2%), **S3** was obtained in 81% yield (524.88 mg). ^1H NMR (400 MHz, acetone- d_6) δ 8.64 (dd, $J = 4.5, 1.5$ Hz, 4H), 7.50 (dd, $J = 4.5, 1.5$ Hz, 6H), 7.44 – 7.20 (m, 10H), 5.25 (s, 2H), 4.43 (d, $J = 24.0$ Hz, 4H), 1.46 (s, 9H).

S3 (400 mg, 0.66 mmol) was added to THF at room temperature. Trifluoromethanesulfonic acid (150.51mg, 1.32 mmol) was added to the stirred solution for an hour. Neutralize the solution to neutral

15 by adding 10% sodium hydroxide solution, the solvent was extracted in $\text{CH}_2\text{Cl}_2/\text{H}_2\text{O}$ mixture (100/50 mL). The organic phase was washed with H_2O (3×100 mL). The organic phases were collected and dried over anhydrous Na_2SO_4 , and the solution was evaporated in vacuo. Donor **D** was obtained in 92% yield (307.01 mg). ^1H NMR (400 MHz, acetone- d_6) δ 8.70-8.57 (m, 4H), 7.53-7.17 (m, 16H), 5.24 (s, 2H), 3.79 (d, $J = 6.7$ Hz, 4H). ^{13}C NMR (126 MHz, acetone- d_6) δ 159.02 (s), 150.09 (s), 141.11 (d, $J = 20$ 13.6 Hz), 134.99 (s), 130.34 (s), 128.32-127.92 (m), 127.65 (s), 127.48 (s), 126.57 (s), 125.34 (s),

123.76 (s), 119.10 (s), 91.92 (s), 87.15 (s), 70.02 (s), 52.77 (s), 52.46 (s). MALDI-TOF-MS of **D**: m/z calcd for C₃₅H₂₇N₃O: 505.62, Found: 506.1.


Scheme S2. The synthetic procedure for the crown ether containing **C1**.



5 To the mixture of crown ether **C2** (580 mg, 1.14 mmol) and compound **S4** (702.1 mg, 1.04 mmol) in dry CH₂Cl₂ (30 mL) was added DMAP (139.3 mg, 1.14 mmol) and EDCI (218.5 mg, 1.14 mmol) under stirring. The mixture was stirred overnight under Ar atmosphere. Next, the mixture was stirred for two hours and poured into 50 mL deionized water then the aqueous phase was extracted with CH₂Cl₂ (3 × 50 ml). The solvent was removed in vacuo to give a colorless liquid, and the residue was
10 purified by column chromatography (SiO₂, CH₂Cl₂/MeOH = 100/1) to give compound **C3** (606.1 mg, 50 %) as a colorless viscous liquid. ¹H NMR (500 MHz, CDCl₃) δ 7.25 (s, 2H), 7.01-6.79 (m, 6H), 5.21 (s, 2H), 4.58 (d, *J* = 7.6 Hz, 2H), 4.19-4.08 (m, 6H), 4.04-3.94 (m, 6H), 3.91 (s, 6H), 3.83 (t, *J* = 7.2 Hz, 6H), 1.84-1.68 (m, 6H), 1.44 (dt, *J* = 14.6, 7.1 Hz, 6H), 1.38-1.18 (m, 30H), 0.88 (t, *J* = 6.9 Hz, 9H). To the mixture of crown ether **C3** (300 mg, 0.26 mmol) and compound **S5** (247.9 mg, 0.33
15 mmol) in dry CH₂Cl₂ (30 mL) was added DMAP (31.5 mg, 0.26 mmol) and EDCI (197.4 mg, 0.99 mmol) under stirring. The mixture was stirred overnight under Ar atmosphere. Next, the mixture was stirred for two hours and poured into 50 mL deionized water then the aqueous phase was extracted with CH₂Cl₂ (3 × 50 ml). The solvent was removed in vacuo to give a colorless liquid, and the residue was purified by column chromatography (SiO₂, CH₂Cl₂/MeOH = 100/1) to give compound **C1** (392.8
20 mg, 80 %) as a colorless waxy solid. ¹H NMR (400 MHz, acetone-*d*₆) δ 7.34 (s, 2H), 7.29 (s, 2H), 7.10 (s, 2H), 7.01 (d, *J* = 8.2 Hz, 2H), 6.95 (d, *J* = 8.1 Hz, 2H), 5.24 (s, 4H), 4.25-4.10 (m, 14H), 4.02 (q, *J* = 6.4 Hz, 6H), 3.88-3.80 (m, 12H), 3.80-3.71 (m, 10H), 3.66 (dt, *J* = 8.1, 4.7 Hz, 6H), 3.63-3.51 (m, 24H), 3.48-3.41 (m, 6H), 3.27 (d, *J* = 3.2 Hz, 8H), 1.86-1.67 (m, 6H), 1.52 (dd, *J* = 14.9, 7.2 Hz, 6H), 1.29 (s, 47H), 0.88 (dd, *J* = 7.4, 6.0 Hz, 9H). ¹³C NMR (126 MHz, CDCl₃) δ 170.66, 158.17, 157.79, 25 154.70- 154.12, 148.20, 147.66, 134.68, 130.20, 126.64, 119.92, 119.26, 114.11, 113.02, 78.07, 77.60,

76.99, 76.15, 75.95-75.22, 74.97-74.59, 74.53, 74.27, 74.04, 71.46, 63.15, 37.01, 35.53, 35.00-34.56, 31.26, 27.69, 18.74.

Scheme S3. The synthetic procedure for the supramolecular [3+3] hexagon **M**.



5 Synthesis of metallacycles 1. Self-assembly of supramolecular [3+3] hexagon **M** from ligand **D** and diplatinum acceptor **A**. The dipyriddyldiol donor ligand **D** (6 mg, 11.87 μmol) and 120° organoplatinum acceptor **A** (13.85 mg, 11.87 μmol) were weighed accurately into a glass vial. To the vial was added 2.0 mL acetone and 0.4 mL H₂O, and the reaction solution was stirred at 50°C for 6 hours. The PF₆⁻ salt of **M** was synthesized by dissolving the NO₃⁻ salt of **M** in acetone/H₂O and adding a saturated 10 aqueous solution of KPF₆ to precipitate the product, which was collected by vacuum filtration. Yield: 18.38 mg, 99%. ¹H NMR (500 MHz, *d*₆-acetone) δ 9.53 (d, *J* = 5.9 Hz, 4H), 8.38 (d, *J* = 6.2 Hz, 4H), 8.15 (d, *J* = 7.8 Hz, 4H), 8.03 (dd, *J* = 17.3, 9.6 Hz, 6H), 7.98-7.88 (m, 7H), 7.84 (d, *J* = 7.5 Hz, 2H), 7.77 (t, *J* = 7.5 Hz, 2H), 7.69 (t, *J* = 7.3 Hz, 1H), 5.72 (s, 2H), 4.25 (t, *J* = 21.6 Hz, 4H), 2.11-1.84 (m, 24H), 1.84-1.52 (m, 36H). ¹³C NMR (126 MHz, *d*₆-acetone) δ 159.04, 150.10, 141.11, 135.00, 130.34, 128.67-127.74, 127.65, 127.46, 126.56, 125.33, 123.77, 119.11, 91.87, 87.12, 70.03, 52.74, 52.42. ³¹P NMR (acetone-*d*₆, 161.9 MHz): δ 14.18 (s). ESI-TOF-MS of **M**: calcd for [M-4PF₆]⁴⁺: 1233.65,

found: 1233.65; calcd for $[M-5PF_6]^{5+}$: 958.14, found: 958.09.

3. The construction and characterization of metallacycle **M**.




Figure S1. Partial 1H NMR spectra of 120°donor **D** and hexagon metallacycle **M** (500 MHz, 298K) in 5 acetone- d_6 .






Figure S2. Partial ^{31}P NMR spectra of 120°donor **A** and hexagon metallacycle **M** (500 MHz, 298K) in acetone- d_6 .







Figure S3. ^1H - ^1H COSY NMR (a), ^1H - ^1H NOESY NMR (b) and 2D DOSY NMR (c) spectra of 1.5 mM hexagonal metallacycles **M** in acetone- d_6 (500 MHz, 298 K).



5 Figure S4. Theoretical (top) and experimental (bottom) ESI-TOF-MS spectra for the different charge states (5+ to 4+) observed from of hexagonal metallacycle **M** (PF_6^- as counterion).




Figure S5. ^1H NMR spectra (500 MHz, acetone- d_6 , 298K) of (a) **D** (16.0 mM) (b) **D** + 1.0 equiv. TfOH, (c) **D** + 1.0 equiv. TfOH + 1.0 equiv. **C1**, (d) **D** + 1.0 equiv. TfOH +1.0 equiv. **C1** + 2.0 DIEA.




Figure S6. ¹H NMR spectra (500 MHz, acetone-*d*₆, 298K) and ³¹P NMR spectra of (a) **M** (1.5 mM) (b) **M** + 3.0 equiv. TfOH, (c) **M** + 3.0 equiv. TfOH +3.0equiv. **C1**, (d) **M**+ 3.0 equiv. TfOH +3.0 equiv. **5 C1**+6.0 DIEA.




Figure S7. Partial $^1\text{H}\{^{31}\text{P}\}$ NMR spectra of dibenzylamine containing metallacycle **M** (a), **M**+heparin (b), and self-assembly **M** + heparin + 3.0 equiv. TfOH (c) (500 MHz, acetone- d_6 and deuterium oxide 5 (v/v, 5/1), 298 K).




Figure S8. The partial ^1H NMR spectra (500 MHz, acetone- d_6 and deuterium oxide (v/v, 3/1), 298 K)

of (a) **D** (16 mM) (b) **D** + 1.0 equiv. TfOH, (c) **D** + 1.0 equiv. TfOH + 0.1 mg heparin.




Figure S9. Dynamic Light Scattering: size distributions of 0.03 mM metallacycle **M** (a), heparin (b), 0.03 mM **M** + 3.0 equiv. TfOH + 3.0 equiv. **C1** (c), 0.03 mM **M** + heparin (d), 0.03 mM **M** + (heparin) + (**C1**)₃ (e).




Figure S10. SEM images of building block **D** (0.2 mM) (a) and metallacycle **M** (1.0 mM) (b) prepared in acetone.





Figure S11. Concentration-dependent SEM images of metallacycle **M** + 3.0 equiv. TfOH + 3.0 equiv. **C1** + Heparin + 6.0 equiv. DIEA + 9.0 equiv. TfOH: (a) ca. 0.01 mM; (b) ca. 0.02 mM; (c) ca. 0.1 mM.

5. Multiple nuclear NMR (^1H and ^{13}C NMR) spectra and MS of new compounds.



5 Figure S12. (a) ^1H NMR and (b) ^{13}C NMR spectra of the donor **D** in CD_3COCD_3 ; (c) ESI-TOF-MS of

D: Exact mass calcd. For C₃₅H₂₇N₃O: 505.62, Found: 506.1.





Figure S13. (a) ¹H NMR spectrum and (b) ¹³C NMR spectrum of **C2** (500 MHz, acetone-*d*₆, 298K).







Figure S14. (a) ^1H NMR spectrum and (b) ^{13}C NMR spectrum of **C1** (500 MHz, acetone- d_6 , 298K).






Figure S15. (a) ^1H NMR spectrum, (b) ^{13}C NMR spectrum of metallacycle **M** and (c) ^{31}P NMR spectrum (500 MHz, acetone- d_6 , 298K).